Delivery Order SPE2DB20D3505-SPE2DB21FU4C7
Award Date
9/8/21
Potential Completion Date
9/9/21
Potential Value
$22K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $2,559.66 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 25, 2024, with a completion date of January 26, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., also known as Amerisourcebergen. The contract is part of a larger $999,999,999.00 Indefinite Delivery Contract...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $21,768.97 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award has an ultimate completion date of May 4, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, particularly the Department...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The $18,619.12 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of October 25, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract, valued at $43,718.11, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a firm fixed-price delivery order with an ultimate completion date of December 7, 2023. The award is not designated with a set-aside and appears to be made through full and open competition. Amerisourcebergen...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA) Troop Support Medical. The $2,446.44 fixed-price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 22, 2022 and does not utilize any set-aside designations. Amerisourcebergen Drug Corp, a subsidiary of the parent company...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $13,741.13 firm fixed-price delivery order was issued to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on November 15, 2021. The contract has an ultimate completion date of November 16, 2021 and was not designated as a set-aside. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora,...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $10,022.62 firm fixed-price delivery order was issued to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. This award is part of Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a range of pharmaceutical products and medical supplies to support military...
This federal contract award is for the supply of RESTASIS 0.05% EYE EMULSION 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,299.77 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of January 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $1,298.10, was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
This federal contract award is for the delivery of RESTASIS 0.05% Eye Emulsion to the Defense Logistics Agency (DLA). The $3,519 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of August 23, 2022 and was awarded on August 22, 2022. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...